Algernon Pharmaceuticals (Algernon Pharmaceuticals) Gross-Profit-to-Asset % : 0.00% (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Algernon Pharmaceuticals's annualized Gross Profit for the quarter that ended in Nov. 2023 was $0.00 Mil. Algernon Pharmaceuticals's average Total Assets over the quarter that ended in Nov. 2023 was $3.00 Mil. Therefore, Algernon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Nov. 2023 was 0.00%.

Algernon Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Algernon Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Gross-Profit-to-Asset % Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Algernon Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Algernon Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Gross-Profit-to-Asset % falls into.

Algernon Pharmaceuticals Gross-Profit-to-Asset % Calculation

Algernon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Aug. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Aug. 2023 )	/	( (Total Assets (A: Aug. 2022 )	+	Total Assets (A: Aug. 2023 ))	/ count )
	=	0	/	( (6.303	+	3.112)	/ 2 )
	=	0	/	4.7075
	=	0.00 %

Algernon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Nov. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Nov. 2023 )	/	( (Total Assets (Q: Aug. 2023 )	+	Total Assets (Q: Nov. 2023 ))	/ count )
	=	0	/	( (3.112	+	2.882)	/ 2 )
	=	0	/	2.997
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Nov. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Algernon Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.